{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:42:17Z","timestamp":1765827737402,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.1007\/s11239-019-01823-y","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T06:18:40Z","timestamp":1550729920000},"page":"345-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial"],"prefix":"10.1007","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00412984","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-9581","authenticated-orcid":false,"given":"Jeffrey B.","family":"Washam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freek W. A.","family":"Verheugt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the ARISTOTLE Committees and Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"1823_CR1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992","journal-title":"N Engl J Med"},{"key":"1823_CR2","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin k antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th\u00a0edn). Chest 133:160S\u2013198S","journal-title":"Chest"},{"key":"1823_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","volume":"159","author":"RD Lopes","year":"2010","unstructured":"Lopes RD, Alexander JH, Al-Khatib SM et al (2010) Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale. Am Heart J 159:331\u2013339","journal-title":"Am Heart J"},{"key":"1823_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"1823_CR5","unstructured":"Drug Development and Drug Interactions: Table of substrates, inhibitors and inducers (FDA). US Food and Drug Administration (2014) http:\/\/www.Fda.Gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.Htm. Accessed 19 Oct 2018"},{"key":"1823_CR6","doi-asserted-by":"publisher","first-page":"i2868","DOI":"10.1136\/bmj.i2868","volume":"353","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM et al (2016) Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: Post hoc analysis of the ARISTOTLE trial. BMJ 353:i2868","journal-title":"BMJ"},{"key":"1823_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Hellkamp AS, Washam JB et al (2016) Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 133:352\u2013360","journal-title":"Circulation"},{"key":"1823_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Raparelli V, Olshansky B, Lip GY (2016) Polypharmacy and major adverse events in atrial fibrillation: Observations from the affirm trial. Clin Res Cardiol 105:412\u2013420","journal-title":"Clin Res Cardiol"},{"key":"1823_CR9","unstructured":"Eliquis (prescribing information) (apixaban) (2017) Bristol-Myers Squibb Co. Princeton, NJ. https:\/\/packageinserts.Bms.Com\/pi\/pi_eliquis.Pdf. Accessed 12 Dec 2017"},{"key":"1823_CR10","unstructured":"European Medicines Agency http:\/\/www.Ema.Europa.Eu\/docs\/en_gb\/document_library\/epar-_product_information\/human\/002148\/wc500107728.Pdf. Accessed 1 May 2018"},{"key":"1823_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"SH Chang","year":"2017","unstructured":"Chang SH, Chou IJ, Yeh YH et al (2017) Association between use of non-vitamin k oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 318:1250\u20131259","journal-title":"JAMA"},{"key":"1823_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","volume":"12","author":"C Voukalis","year":"2016","unstructured":"Voukalis C, Lip GY, Shantsila E (2016) Drug-drug interactions of non-vitamin k oral anticoagulants. Expert Opin Drug Metab Toxicol 12:1445\u20131461","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-019-01823-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01823-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T14:33:50Z","timestamp":1628606030000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-019-01823-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4,15]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01823-y","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"21 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Washam: None. Hohnloser: Consulting\/Lecture fees from Boehringer Ingelheim, St Jude Medical, Sanofi Aventis, Cardiome. Lopes: Research grants from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer; Consultant\/Advisory Board fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Merck, Portola, GlaxoSmithKline, Pfizer. Wojdyla: None. Vinereanu: Research grants from GlaxoSmithKline, Pfizer, Bristol-Myers Squibb. Alexander: Institutional research grants from Bristol-Myers Squibb, Boehringer Ingelheim, CryoLife, CSL Behring, the US Food and Drug Administration, the National Institutes of Health, Tenax Therapeutics, and VoluMetrix; Consulting fees\/Honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Novo Nordisk Pharmaceuticals, Pfizer, Portola Pharmaceuticals, VA Cooperative Studies Program, and Zafgen. Gersh: Consultant\/Advisory Board fees from Boston Scientific Corporation, Cardiovascular Research Foundation, Coretherapix, Duke Clinical Research Institute, Duke University, Icahn School of Medicine at Mount Sinai, Janssen Research and Development, Janssen Scientific Affairs, Kowa Research Institute, Inc., Medtronic, Mount Sinai St. Luke\u2019s, Sirtex Medical Limited, Teva Pharmaceutical Industries, Thrombosis Research Institute. Hanna: Employee of Bristol-Myers Squibb at the time the trial was conducted. Horowitz: None. Hylek: Research grants from Bristol Myers Squibb\/Pfizer, Janssen; Consulting fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb\/Pfizer, Janssen, Medtronic, Portola. Xavier: None. Verheugt: Consulting fees\/Honoraria from Bayer Healthcare, Boehringer Ingelheim, BMS\/Pfizer, Daiichi Sankyo. Wallentin: Institutional research grants from Bristol-Myers Squibb\/Pfizer, AstraZeneca, Merck, Boehringer Ingelheim, and GlaxoSmithKline; Consulting fees from GlaxoSmithKline, Bristol-Myers Squibb\/Pfizer, Abbott, AstraZeneca, and Boehringer Ingelheim. Granger: Research grants from Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi, GlaxoSmithKline, Janssen, Medtronic Foundation, Novartis, Pfizer, The Medicines Company; Consultant\/Advisory Board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Inc, GlaxoSmithKline, Hoffman LaRoche, Janssen, Medtronic, Novartis, Pfizer, The Medicines Company, Verseon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}